.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH03_Saxagliptin.Saxagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH03_Saxagliptin.Saxagliptin| name: | Saxagliptin |
| ATC code: | A10BH03 | route: | oral |
| n-compartments | 2 |
Saxagliptin is an oral antidiabetic medication used for the treatment of type 2 diabetes mellitus. It is a selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, which increases incretin levels (GLP-1 and GIP), inhibiting glucagon release and increasing insulin secretion. Saxagliptin is approved and widely used today as a second-line therapy for glycemic control.
Pharmacokinetic parameters reported for healthy adult human subjects, both male and female, following a single oral 5 mg dose under fasting conditions.
Boulton, DW, et al., & Lacreta, F (2013). Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. British journal of clinical pharmacology 75(3) 763–768. DOI:10.1111/j.1365-2125.2012.04391.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22823746
Li, H, et al., & Zhao, J (2012). Pharmacokinetic study of saxagliptin in healthy Chinese subjects. Clinical drug investigation 32(7) 465–473. DOI:10.2165/11598760-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22668067
Scheen, AJ (2015). Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clinical pharmacokinetics 54(1) 1–21. DOI:10.1007/s40262-014-0198-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25331711